Propensities of Fatty Acid-Modified ASOs: Self-Assembly vs Albumin Binding-Reference-Cited by-同舟云学术

Propensities of Fatty Acid-Modified ASOs: Self-Assembly vs Albumin Binding

Published:2023-05-05 Issue:5 Volume:34 Page:866-879
ISSN:1043-1802
Container-title:Bioconjugate Chemistry
language:en
Short-container-title:Bioconjugate Chem.

Author:

Kusznir Eric-André¹,Hau Jean-Christophe¹,Portmann Michaela²,Reinhart Anne-Gaëlle²,Falivene Fabio²,Bastien Jessica³,Worm Jesper⁴,Ross Alfred²,Lauer Matthias¹,Ringler Philippe⁵,Sladojevich Filippo²,Huber Sylwia¹,Bleicher Konrad³,Keller Michael²^ORCID

Affiliation:

1. Roche Pharma Research and Early Development, Therapeutic Modalities, Lead Discovery, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland

2. Roche Pharma Research and Early Development, Therapeutic Modalities, pCMC, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland

3. Roche Pharma Research and Early Development, Therapeutic Modalities, RMR, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland

4. Roche Pharma Research and Early Development, Therapeutic Modalities, RMR, Roche Innovation Center Copenhagen, F. Hoffmann-La Roche Ltd., Fremtidsvej 3, 2970 Hoersholm, Denmark

5. Biozentrum, University of Basel, Spitalstrasse 41, CH - 4056 Basel, Switzerland

Funder

F. Hoffmann-La Roche

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Pharmaceutical Science,Pharmacology,Biomedical Engineering,Bioengineering,Biotechnology

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.bioconjchem.3c00085

Reference47 articles.

1. The Interaction of Phosphorothioate-Containing RNA Targeted Drugs with Proteins Is a Critical Determinant of the Therapeutic Effects of These Agents

2. Phosphorothioate modified oligonucleotide–protein interactions